PHAR
Closed
Pharming Group Nv
10.71
+0.02 (+0.19%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 10.69
Day's Range: 10.71 - 10.71
Send
sign up or login to leave a comment!
When Written:
11.91
Pharming Group NV is a biopharmaceutical company that specializes in the development of innovative protein replacement therapies and precision medicines for rare diseases. The company's lead product, Ruconest, is a recombinant human C1 inhibitor approved for the treatment of hereditary angioedema (HAE) attacks in Europe, the US, and other countries. Pharming also has a pipeline of other products in development for HAE and other diseases, including Pompe disease and Fabry disease.
Pharming was founded in 1988 and is headquartered in Leiden, the Netherlands. The company has a global presence, with operations in Europe, the US, and Asia. Pharming is publicly traded on the Euronext Amsterdam stock exchange and has a market capitalization of approximately €2.5 billion as of August 2021.
In addition to Ruconest, Pharming has a number of other products in development, including a next-generation version of Ruconest, a gene therapy for Pompe disease, and a precision medicine for Fabry disease. The company also has a platform technology called Pharming Connect, which enables the rapid development of new protein therapeutics for a range of diseases.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Pharming was founded in 1988 and is headquartered in Leiden, the Netherlands. The company has a global presence, with operations in Europe, the US, and Asia. Pharming is publicly traded on the Euronext Amsterdam stock exchange and has a market capitalization of approximately €2.5 billion as of August 2021.
In addition to Ruconest, Pharming has a number of other products in development, including a next-generation version of Ruconest, a gene therapy for Pompe disease, and a precision medicine for Fabry disease. The company also has a platform technology called Pharming Connect, which enables the rapid development of new protein therapeutics for a range of diseases.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!